Dashboard
1
The company declared positive results in Mar'25 after negative results in Dec'24
- OPERATING CASH FLOW(Y) Highest at CNY 4,888.72 MM
- INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
- RAW MATERIAL COST(Y) Fallen by -7.16% (YoY)
2
With ROE of 12.59%, it has a attractive valuation with a 2.42 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 97,589 Million (Large Cap)
19.00
NA
4.43%
-0.33
12.59%
2.42
Revenue and Profits:
Net Sales:
10,343 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,717 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.23%
0%
-6.23%
6 Months
-2.6%
0%
-2.6%
1 Year
-3.04%
0%
-3.04%
2 Years
10.69%
0%
10.69%
3 Years
-1.94%
0%
-1.94%
4 Years
-12.29%
0%
-12.29%
5 Years
-20.84%
0%
-20.84%
Yunnan Baiyao Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.45%
EBIT Growth (5y)
4.90%
EBIT to Interest (avg)
49.51
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
0.91
Tax Ratio
19.42%
Dividend Payout Ratio
44.52%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
15.36%
ROE (avg)
10.59%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
2.42
EV to EBIT
17.62
EV to EBITDA
16.36
EV to Capital Employed
3.11
EV to Sales
2.08
PEG Ratio
1.27
Dividend Yield
4.43%
ROCE (Latest)
17.64%
ROE (Latest)
12.59%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Jun 2017
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
10,343.50
10,787.90
-4.12%
Operating Profit (PBDIT) excl Other Income
1,389.50
2,066.20
-32.75%
Interest
4.60
6.20
-25.81%
Exceptional Items
29.10
41.00
-29.02%
Consolidate Net Profit
1,717.10
1,927.50
-10.92%
Operating Profit Margin (Excl OI)
124.80%
182.40%
-5.76%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -4.12% vs 7.42% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -10.92% vs 340.67% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
39,790.20
38,900.50
2.29%
Operating Profit (PBDIT) excl Other Income
4,923.30
3,994.50
23.25%
Interest
73.90
58.60
26.11%
Exceptional Items
103.30
66.20
56.04%
Consolidate Net Profit
4,767.10
4,122.60
15.63%
Operating Profit Margin (Excl OI)
114.90%
93.10%
2.18%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 2.29% vs 7.23% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 15.63% vs 45.14% in Dec 2023
About Yunnan Baiyao Group Co., Ltd. 
Yunnan Baiyao Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






